InMode Ltd. (NASDAQ:INMD) Shares Sold by Seizert Capital Partners LLC

Seizert Capital Partners LLC cut its stake in InMode Ltd. (NASDAQ:INMD) by 1.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,144 shares of the healthcare company’s stock after selling 1,219 shares during the period. Seizert Capital Partners LLC’s holdings in InMode were worth $2,070,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Asset Dedication LLC acquired a new stake in shares of InMode in the 2nd quarter worth about $33,000. Headlands Technologies LLC raised its holdings in shares of InMode by 118.2% during the first quarter. Headlands Technologies LLC now owns 1,916 shares of the healthcare company’s stock valued at $41,000 after buying an additional 1,038 shares during the last quarter. nVerses Capital LLC acquired a new position in shares of InMode during the second quarter worth approximately $42,000. Nisa Investment Advisors LLC grew its holdings in InMode by 314.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after buying an additional 2,694 shares in the last quarter. Finally, EMC Capital Management bought a new position in InMode in the 1st quarter worth approximately $90,000. 68.04% of the stock is currently owned by institutional investors.

InMode Stock Down 5.2 %

Shares of INMD stock opened at $18.01 on Friday. The stock has a 50-day simple moving average of $17.23 and a 200 day simple moving average of $17.45. The stock has a market capitalization of $1.51 billion, a P/E ratio of 9.74 and a beta of 2.15. InMode Ltd. has a fifty-two week low of $14.87 and a fifty-two week high of $26.80.

Analyst Ratings Changes

Several analysts have weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research note on Thursday, October 31st. Jefferies Financial Group cut shares of InMode from a “buy” rating to a “hold” rating and cut their price objective for the company from $21.00 to $19.00 in a research note on Tuesday, July 23rd. BTIG Research began coverage on shares of InMode in a research report on Thursday, October 17th. They issued a “buy” rating and a $25.00 target price for the company. Finally, Barclays lowered their target price on shares of InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a research note on Monday, October 14th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $22.60.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.